Ascletis Pharma, Inc. (ASCLF)
0.72
-0.01
(-1.37%)
USD |
OTCM |
Oct 27, 16:00
Ascletis Pharma Enterprise Value : 667.59M for Oct. 27, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 27, 2026 | 667.59M |
| October 26, 2026 | 678.14M |
| October 23, 2026 | 678.14M |
| October 22, 2026 | 678.14M |
| October 21, 2026 | 720.34M |
| October 20, 2026 | 699.24M |
| October 19, 2026 | 699.24M |
| October 16, 2026 | 699.24M |
| October 15, 2026 | 699.24M |
| October 14, 2026 | 699.24M |
| October 13, 2026 | 836.39M |
| October 12, 2026 | 836.39M |
| October 09, 2026 | 1.058B |
| October 08, 2026 | 1.058B |
| October 07, 2026 | 1.058B |
| October 06, 2026 | 1.005B |
| October 05, 2026 | 1.005B |
| October 02, 2026 | 1.005B |
| October 01, 2026 | 1.090B |
| September 30, 2026 | 1.090B |
| September 29, 2026 | 1.026B |
| September 28, 2026 | 1.174B |
| September 25, 2026 | 1.174B |
| September 24, 2026 | 1.174B |
| September 23, 2026 | 1.174B |
| Date | Value |
|---|---|
| September 22, 2026 | 1.174B |
| September 21, 2026 | 1.174B |
| September 18, 2026 | 1.068B |
| September 17, 2026 | 1.068B |
| September 16, 2026 | 1.068B |
| September 15, 2026 | 1.174B |
| September 14, 2026 | 1.174B |
| September 11, 2026 | 1.185B |
| September 10, 2026 | 1.279B |
| September 09, 2026 | 1.279B |
| September 08, 2026 | 1.279B |
| September 04, 2026 | 1.279B |
| September 03, 2026 | 1.258B |
| September 02, 2026 | 1.258B |
| September 01, 2026 | 1.258B |
| August 31, 2026 | 1.279B |
| August 28, 2026 | 1.279B |
| August 27, 2026 | 1.279B |
| August 26, 2026 | 1.279B |
| August 25, 2026 | 1.279B |
| August 24, 2026 | 1.279B |
| August 21, 2026 | 1.279B |
| August 20, 2026 | 1.279B |
| August 19, 2026 | 1.279B |
| August 18, 2026 | 1.279B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| CStone Pharmaceuticals Co. Ltd. | 974.27M |
| RemeGen Co., Ltd. | 4.874B |
| InnoCare Pharma Ltd. | 1.921B |
| Adagene, Inc. | 260.51M |
| JW (Cayman) Therapeutics Co. Ltd. | -- |
Enterprise Value Related Metrics
| Earnings Yield | -11.65% |
| Normalized Earnings Yield | -12.26 |